Potassium may lower blood pressure, but the authors of a new review in the Journal of the American Heart Association note that its effect in untreated primary hypertension "remains uncertain." Their review put a number on it for that one group: adults with high blood pressure who weren't yet taking anything for it. In that group, potassium supplements lowered clinic readings by about 5 points.
That's a useful finding. It's also a narrower one than the headline makes it sound, and people already taking blood pressure medicine weren't in it.
What the review did
Researchers at Universidad Peruana Cayetano Heredia in Lima searched for randomized trials in adults with untreated primary hypertension, meaning high blood pressure without another known cause and not yet on treatment. Every trial compared oral potassium supplements with a placebo, sodium chloride or no treatment. The review plan was registered in advance (PROSPERO CRD42024621287), and the searches ran through January 31, 2025, with an update on October 1, 2025.
They found 19 trials with 803 participants in total. Fourteen were crossover trials, where the same people take both the supplement and the comparison in turn, and five were parallel trials. The median trial lasted 4 weeks.
What it found
- Clinic blood pressure: systolic (the top number) fell by 5.3 mm Hg (95% CI 4.4 to 6.3), and diastolic (the bottom number) by 4.5 mm Hg (95% CI 3.9 to 5.1).
- 24-hour ambulatory blood pressure, measured by a cuff worn through a normal day and night: the reductions were smaller, 2.8 mm Hg systolic (95% CI 1.3 to 4.3) and 3.2 mm Hg diastolic (95% CI 2.2 to 4.2).
- Side effects: adverse events were more frequent with potassium, 12.8% versus 3.2%. Dropping out of a trial, including because of adverse events, was uncommon.
The authors' own summary is measured. Potassium "modestly reduces clinic BP," they wrote, and may produce smaller reductions on 24-hour monitoring.
What it can't tell us
Four weeks (the median trial length) is a short time. A blood pressure number moved, but the review reports blood pressure readings, not strokes or heart attacks, and makes no claim about those.
The authors flag the weak spots themselves: heterogeneity was substantial (the trials disagreed with each other more than chance would explain), evidence from 24-hour monitoring was limited, and safety data were limited. They call for "cautious interpretation." The headline numbers were pooled with common-effect models, with random-effects models run only as a sensitivity check, which I'd keep in mind given how much the trials disagreed. The gap between the clinic number and the 24-hour number matters too, since the 24-hour reading covers a whole day and night rather than one clinic visit.
The abstract doesn't say what doses or forms of potassium the trials used, and we worked from the abstract alone, so it can't tell you how a particular bottle on the shelf compares. And again: everyone in these trials was untreated. The results don't describe what happens when potassium is added on top of blood pressure medicine.
Who should ask before trying it
This is where the prescription label is more useful than the review. We read the current DailyMed label for potassium chloride extended-release tablets, a prescription product meant for treating and preventing low potassium. It's written for a prescription medicine, not for over-the-counter supplements, but its warnings show who needs to be careful with extra potassium. They are about too much potassium in the blood, called hyperkalemia:
- Triamterene or amiloride (potassium-sparing diuretics): the label says potassium chloride is contraindicated with them, because the combination can produce severe hyperkalemia.
- ACE inhibitors, ARBs, spironolactone, eplerenone or aliskiren: these cause the body to hold on to potassium, and the label says to closely monitor potassium in people taking them. Lisinopril and losartan are common examples (see lisinopril and potassium, losartan and potassium and spironolactone and potassium).
- NSAIDs such as ibuprofen: the label says they may also cause potassium retention and calls for close monitoring.
- Kidney problems: with normal kidneys, the label says oral potassium rarely causes serious hyperkalemia, but if the kidneys can't clear it, potentially fatal hyperkalemia can result.
The label adds that hyperkalemia is usually asymptomatic. You often can't feel it; it shows up on a blood test. That's the real reason to ask before adding potassium, rather than waiting to see how you feel.
Note the irony: several of those medicines are blood pressure drugs. The people most interested in a blood pressure supplement are often the people the label warns about. If that's you, this isn't a reason to change anything you're prescribed. Bring the potassium bottle to your doctor or pharmacist and ask whether it fits with your medicines and your latest kidney and potassium blood tests.
There's more on the mineral itself on our potassium page. If you add a potassium supplement with your doctor's OK, Pilora's interaction checker can flag it against the medicines already on your list.
The bottom line
In people with untreated high blood pressure, potassium supplements lowered clinic readings by about 5 points in short trials, less on 24-hour monitoring, with more adverse events reported than in the comparison groups. It's a modest, real effect, not a replacement for treatment. If you take an ACE inhibitor, an ARB, spironolactone, a potassium-sparing diuretic or regular NSAIDs, or have kidney disease, ask your doctor or pharmacist before you start.
